前沿生物股价涨5.1%，汇添富基金旗下1只基金重仓，持有6744股浮盈赚取5192.88元

Group 1 - Frontier Biopharmaceuticals (Nanjing) Co., Ltd. is a biopharmaceutical company focused on researching, developing, producing, and selling innovative drugs to meet significant unmet clinical needs [1] - The company has an original anti-HIV drug that is patented in major global markets, along with two new drugs in clinical trials that are also patented or licensed [1] - The revenue composition of the company is primarily from its anti-HIV drug, accounting for 91.29%, with other products making up 8.71% [1] Group 2 - As of the second quarter, Huatai-PineBridge Fund holds 6,744 shares of Frontier Biopharmaceuticals in its portfolio, unchanged from the previous period, representing 0.07% of the fund's net value [2] - The fund has generated a floating profit of approximately 5,192.88 yuan from its investment in Frontier Biopharmaceuticals [2] - The fund, established on April 14, 2017, has a total size of 86.19 million yuan and has returned 0.32% year-to-date, ranking 8019 out of 8174 in its category [2]